Connect with us

Health

Sacubitril/Valsartan Treatment for HFpEF Shown to Reduce NT-proBNP Levels – AJMC.com Managed Markets Network

Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators…

Published

on

Article feature image

Among several measures evaluated in a 24-week, randomized, double-blind, parallel group clinical trial comparing outcomes among patients with heart failure with preserved ejection fraction (HFpEF; left ventricular ejection fraction > 40%), sacubitril/valsartan…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending